El 21 de marzo de 2023, LienTeh anunció una nueva estrategia de contenido destinada a proporcionar información y servicios de longevidad útiles, confiables y centrados en el usuario. Anteriormente, la Red LienTeh se creó originalmente para brindar apoyo durante la pandemia de COVID-19 al promover el equilibrio de atención médica…
On March 21, 2023, LienTeh announced a new content strategy aimed at providing useful, reliable and user-centric longevity information and services. Previously,The LienTeh Network was originally created to provide support during the COVID-19 pandemic by promoting cross-regional healthcare balance and improving access to healthcare resources. After that, the LienTeh network…
Las principales terapias dirigidas para la Leucemia Mieloide Aguda (AML, por sus siglas en inglés) incluyen: El texto original en inglés es más preciso 10 targeted therapies for Acute Myeloid Leukemia[AML] Inhibidores de FLT3 Para AML con mutaciones FLT3, como midostaurina , gilteritinib, etc. Estos se dirigen a la tirosina…
The main targeted therapies for Acute Myeloid Leukemia (AML) include: FLT3 inhibitors For AML with FLT3 mutations, such as midostaurin, gilteritinib, etc. These target the FLT3 tyrosine kinase. Midostaurin[1] On April 28, 2017, the U.S. Food and Drug Administration approved midostaurin (RYDAPT, Novartis Pharmaceuticals Corp.) for the treatment of adult patients with newly diagnosed acute myeloid leukemia…
VIENTIANE, LAO PDR, March 6, 2023 -- The Lao Ministry of Health and the World Health Organization hosted an important GMP quality improvement meeting in Vientiane on March 1, attended by professionals from the local pharmaceutical industry. The purpose of this conference is to improve the quality of medicines in…
VIENTIANE, VIENTIANE, LAO PDR, March 3, 2023 -- BigBear pharmaceutical.LTD (BigBear pharma) announced that it has obtained the Good Manufacturing Practices (GMP) certificate issued by the Lao Food and Drug Regulatory Authority. The investor team of BigBear pharmaceutical went to Laos to investigate the investment environment in 2021, and formally…
VIENTIANE, LAOS, February 17, 2023 Laos Biospring.LTD and Singapore Zen science announced that the two parties have signed a joint venture agreement to establish a new joint venture company BioZen Health in Laos to engage in the manufacture and sale of high value-added medical beauty products and health food, and…
Ngày 07 tháng 11 năm 2022, Viêng Chăn, Lào - BioSpring ("BioSpring Group.LTD" "BioSpring Group") ra mắt viên nang BIOMOB (Mobocertinib 40mg) để điều trị ung thư phổi không phải tế bào nhỏ (NSCLC) với thụ thể yếu tố tăng trưởng biểu bì ( EGFR) đột biến chèn exon 20…
November 07, 2022, Vientiane, Laos--BioSpring ("BioSpring Group.LTD" "BioSpring Group") is launching BIOMOB (Mobocertinib 40mg) capsules for the treatment of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (Ex20ins) mutation. Mobocertinib is a small molecule tyrosine kinase inhibitor. Its molecular target is epidermal growth factor receptor (EGFR) bearing mutations…
6 октября 2022 г., Вьентьян, Лаос — компания BioSpring («BioSpring Group.LTD», «BioSpring Group») выпускает таблетки BIODEUCRA (деукравацитиниб 6 мг) для лечения взрослых с бляшечным псориазом средней и тяжелой степени, которым показана системная терапия. или фототерапия. Деукравацитиниб, первый в своем классе пероральный селективный ингибитор аллостерической тирозинкиназы 2 (TYK2), является первым одобренным…
10 terapias dirigidas para la Leucemia Mieloide AgudaLa(LMA)10 targeted therapies for Acute Myeloid Leukemia[AML]LienTeh Network Announces New Content Strategy Focused on Lo…LienTeh Network anuncia una nueva estrategia de contenido ce…
ALBA LIST：ALBA Lighting PAP
Copyright © 2021-2022 LienTeh.net All rights reserved.
